The mode of delivery and content of communication strategies used in mandatory and non-mandatory biosimilar transitions: a systematic review with meta-analysis

Gasteiger, Chiara; Broeder, Alfons A den; Stewart, Sarah; Gasteiger, Norina; Scholz, Urte; Dalbeth, Nicola; Petrie, Keith J.

doi:10.1080/17437199.2021.1970610

Cited by 9 publications

(4 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although providers’ attitudes towards biosimilars have been extensively researched, this is the first study to specifically explore providers’ experiences of the transitioning process ( 5 , 6 , 7 , 8 , 9 ). Significant variability is seen in how biosimilars have been adopted and integrated into care globally ( 25 ). However, learning from and sharing experiences is essential to ensure the transition process is optimized and simple for all health care providers involved.…”

Section: Discussionmentioning

confidence: 99%

Health Care Providers’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar

Gasteiger,

Lobo,

Wong

et al. 2023

ACR Open Rheumatology

Self Cite

View full text Add to dashboard Cite

ObjectiveTransitioning patients to biosimilars has become common to reduce costs and improve access. However, it is unclear how the transition process impacts health care providers at the frontline of the brand change. This study explores health care providers’ experiences of a mandatory brand change to an adalimumab biosimilar.MethodsA cross‐sectional study was conducted in Aotearoa New Zealand with 164 providers involved in the nationwide adalimumab brand change. Rheumatologists (n = 39), rheumatology nurses (n = 16), and pharmacists (n = 109) completed a survey that assessed their satisfaction with logistics and supply, information and education, support, and administrative workload and reported what did and did not go well during the transition.ResultsThe mean satisfaction score (0‐10) with the transition was 5.7 (SD = 2.6). Providers were the least satisfied with training for the biosimilar device, information from government agencies, and administrative workload during the transition. Satisfaction with adalimumab safety, efficacy and device quality, and the availability of sharps bins, alcohol wipes, and patient support was lower following the transition. Satisfaction with administrative workload (B = 0.37, P < 0.001) and training for the device (B = 0.20, P = 0.020) predicted overall satisfaction. Providers reported that a poorly implemented initial authorization process, loss of a patient support program, and insufficient communication between providers complicated the transition. The citrate‐free preservative and longer authorization duration after the transition were viewed positively.ConclusionProviders experienced an increased workload and reported less satisfaction with the biosimilar following the transition. Experiences may be improved by ensuring training for the device, a high‐quality patient support program, and functioning authorization processes throughout the transition.

show abstract

Section: Discussionmentioning

confidence: 99%

Health Care Providers’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar

Gasteiger,

Lobo,

Wong

et al. 2023

ACR Open Rheumatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is also important to note that findings and recommendations may not be entirely generalizable to biosimilar transitions where the drug is not administered at home. Contrary to those receiving infusions at a clinic, patients self‐injecting are directly exposed to differences in branding and changes in the administration of the drug (e.g., quality of the device) and, therefore, require additional information and rely on patient support programs ( 32 ). More research is needed to understand patterns of dissatisfaction and predictors of satisfaction with the brand change.…”

Section: Discussionmentioning

confidence: 99%

Rheumatology Patients’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar

Gasteiger,

Lobo,

Stanley

et al. 2023

ACR Open Rheumatology

Self Cite

View full text Add to dashboard Cite

ObjectiveTransitions to biosimilars are common to reduce the cost burden of biologics. While brand changes can be daunting for patients, few studies have explored patients’ experiences with the transitioning process. This study examined rheumatology patients’ experiences with a mandatory nationwide brand change to an adalimumab biosimilar.MethodsPeople with rheumatic diseases involved in the adalimumab transition in Aotearoa New Zealand completed a nationwide online survey. Participants (n = 117, 48% with rheumatoid arthritis) reported their satisfaction with the biosimilar, logistics and supply, information and communication, and availability of support. They also reported what did and did not go well during the transition and provided recommendations for future transitions.ResultsThe mean [SD] satisfaction score with the transition was 6.2 [3.2] on a 0‐10 scale, with 10 indicating high satisfaction. Participants were the least satisfied with the support and information from patient support organizations, and training for the device during the transition. Participants were most satisfied with the biosimilar supply, support from pharmacists, and how early they were informed before the transition occurred. After the transition, participants were less satisfied with the device quality, patient support program, biosimilar safety and efficacy, and the provision of alcohol wipes and sharps bins (p < 0.05 for all). Satisfaction with training for the biosimilar device (B = .25, p = .036) predicted overall satisfaction. Participants appreciated less injection pain and the ease of the biosimilar device. The lack of alcohol wipes and loss of the bio‐originator support program were viewed negatively.ConclusionFuture biosimilar transitions should ensure the availability of alcohol wipes, sharps bins, and a comparable patient support program. Patient support organizations could be involved in providing information to patients about the change.

show abstract

“…For example, one question asked, “will the biosimilar work the same as my current drug?” The development of these questions was informed by a systematic literature review, which identified common information about biosimilars provided in communication strategies globally. 26 An additional four open-ended questions were used to assess pharmacists' concerns about biosimilars in general, the information they perceive important for patients and companions to know, and which resources or information would help them provide better education.…”

Section: Methodsmentioning

confidence: 99%

“… 24 , 25 Understanding how pharmacists specifically explain biosimilars to patients can help guide future educational attempts, as some information, such as cost-saving, may support negative beliefs about quality. 26 …”

Section: Introductionmentioning

confidence: 99%

Pharmacists' confidence in explaining biosimilars to patients before a nationwide medicine change: A cross-sectional study

Gasteiger

Petrie

2022

Exploratory Research in Clinical and Social Pharmacy

Self Cite

View full text Add to dashboard Cite

The mode of delivery and content of communication strategies used in mandatory and non-mandatory biosimilar transitions: a systematic review with meta-analysis

Cited by 9 publications

References 103 publications

Health Care Providers’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar

Health Care Providers’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar

Rheumatology Patients’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar

Pharmacists' confidence in explaining biosimilars to patients before a nationwide medicine change: A cross-sectional study

Contact Info

Product

Resources

About